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Abstract
Background: Theaimof this study wasto providemore insight into the question as to why blockade of CCR1, CCR2, and CCR5
may have failed in clinical trials in rheumatoid arthritis (RA) patients, using an in vitro monocyte migration system model.
Methodology/Principal Findings: Monocytes from healthy donors (HD; n=8) or from RA patients (for CCR2 and CCR5
antibody n=8; for CCR1 blockade n=13) were isolated from peripheral blood and pre-incubated with different
concentrations of either anti-CCR1, anti-CCR2, or anti-CCR5 blocking antibodies (or medium or isotype controls). In addition,
a small molecule CCR1 antagonist (BX471) was tested. Chemotaxis was induced by CCL2/MCP-1 (CCR2 ligand), CCL5/
RANTES (CCR1 and CCR5 ligand), or by a mix of 5 RA synovial fluids (SFs), and cellular responses compared to chemotaxis in
the presence of medium alone. Anti-CCR2 antibody treatment blocked CCL2/MCP-1-induced chemotaxis of both HD and RA
monocytes compared to isotype control. Similarly, anti-CCR5 antibody treatment blocked CCL5/RANTES-induced
chemotaxis of RA monocytes. While neither CCR2 nor CCR5 blocking antibodies were able to inhibit SF-induced monocyte
chemotaxis, even when both receptors were blocked simultaneously, both anti-CCR1 antibodies and the CCR1 antagonist
were able to inhibit SF-induced monocyte chemotaxis.
Conclusions/Significance: The RA synovial compartment contains several ligands for CCR1, CCR2, and CCR5 as well as other
chemokines and receptors involved in monocyte recruitment to the site of inflammation. The results suggest that CCR2 and
CCR5 are not critical for the migration of monocytes towards the synovial compartment in RA. In contrast, blockade of CCR1
may be effective. Conceivably, CCR1 blockade failed in clinical trials, not because CCR1 is not a good target, but because
very high levels of receptor occupancy at all times may be needed to inhibit monocyte migration in vivo.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
characterized by massive infiltration of synovial tissue and synovial
fluid (SF) with immune cells, mediated by chemokines and adhesion
molecules [1,2]. It is well accepted that monocyte/macrophage
numbers are increased in clinically affected joints and these numbers
correlate with the clinical signs and symptoms [3]. Accordingly,
clinical improvement after effective antirheumatic therapy is
consistently associated with reduced macrophage numbers in the
synovium [4]. Taken together, synovial macrophages are considered
key effector cells in the pathogenesis of RA [5,6].
Chemokines play an important role in the accumulation of these
cells at the site of inflammation. They belong to a superfamily of
small (6–14 kDa) structurally related proteins that regulate the
traffic of various leukocytes [7]. Inflammatory chemokines are
expressed in inflamed tissues by resident and infiltrated cells upon
stimulation by pro-inflammatory mediators present in situ.R A
synovial tissue and fluid contain high concentrations of a variety
of inflammatory chemokines [1,8–13] that can interact with
chemokine receptors on the surface of monocytes/macrophages
and contribute to their accumulation at these sites. Specifically,
CCR1 (major ligands CCL3/MIP-1a, CCL5/RANTES and
CCL7/MCP-3), CCR2 (major ligand CCL2/MCP-1), CCR5
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are abundantly expressed by RA monocytes/macrophages [1,10]
suggesting that interference with the migration of these cells by
cytokine receptor blockade might be a successful therapeutic
approach to reduce synovial inflammation. Although CCR2 [14]
and CCR5 [15] receptor blockade has shown positive results in
animal models of RA, targeted CCR2 [16] and CCR5 [17,18]
blockade was not effective in RA patients. In vivo and in vitro
experiments in RA models have also suggested that blocking
CCR1 ligands or the receptor itself may inhibit chemotaxis and
reduce synovial inflammation [13,19,20]. The experience in RA
patients has been variable. The first study testing the effects of
chemokine receptor blockade in human patients was a small phase
1 b proof-of-concept clinical trial in RA patients [21]. This study
demonstrated evidence of a significant biological effect of a CCR1
antagonist in subjects with RA, associated with a trend towards
clinical improvement. Other studies evaluating CCR1 blockade in
RA have however shown no efficacy [22,23]. To provide more
insight into the question as to why these approaches might have
failed, we investigated the effect of specific CCR1, CCR2 or
CCR5 blockade on RA monocyte migration in an in vitro model
evaluating SF-induced chemotaxis.
Methods
Ethical approval
This study was conducted with the approval of the Medical
Ethical Committee of the Academic Medical Center/University of
Amsterdam and all patients gave their written informed consent.
Patients
Peripheral blood was obtained from RA patients [24] with
active disease, defined by the presence of at least one clinically
inflamed joint (for CCR2 or CCR5 antibodies n=8; for CCR1
blockade n=13 in total) and healthy subjects (n=8). None of the
patients was being treated with biologicals. Patient demographic
and clinical features are shown in Table 1.
Synovial fluid samples
Synovial fluid (SF) from patients with RA were collected during
therapeutic arthrocentesis and transferred to heparin containing
tubes. The samples were centrifuged and the supernatants stored
at 280uC until used for the chemotaxis assay. Patient demo-
graphic and clinical features are shown in Table 2.
Multiplex assay for chemokine/cytokine measurement
SFs were analyzed using the Human Cytokine Luminex 27-plex
(BioSource; Invitrogen, Breda, The Netherlands). All reagents
were provided with the BioSource (Invitrogen) kit, and the assay
was performed according to the manufacturer’s instructions.
Monocyte isolation
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll gradient as previously described [25]. Monocytes were
purified by negative selection using Monocyte Isolation Kit II
(Miltenyi Biotec, Bergisch Gladbach, Germany) according to the
manufacturer’s instructions. The purified cells were .95% pure as
determined by FACS analysis. Isolated cells were phenotyped using
anti-CD3-FITC (BD Biosciences, Oxford, United Kingdom),
CD14-APC (BD Biosciences), and anti-CCR2-PE (R&D systems,
Abingdon, United Kingdom), anti-CCR5-PE (BD Biosciences) or
anti-CCR1-PE (R&D systems) conjugated antibodies.
Neutralizing antibodies, isotype controls and small
molecule CCR1 antagonist
The following neutralizing antib o d i e sw e r eag i f tf r o mM i l l e n n i u m
Pharmaceuticals Inc.: mouse anti-human CCR2 (mouse IgG2a; clone
m1D9) and mouse anti-human CCR5 (mouse IgG1; clone 2D7). The
neutralizing antibody against CCR1 (mouse IgG1; clone 141-2) was
purchased from MBL International (Woburn, MA). Functional grade
mouse IgG1 and mouse IgG2a antibodies were used as isotype controls
(both from eBioscience, San Diego, CA) for CCR1/CCR5 and
CCR2, respectively. The small molecule CCR1 antagonist BX471 was
obtained from former Berlex Biosciences (Richmond, CA).
In vitro chemotaxis
Monocytes were first washed in chemotaxis medium (PBS with 1%
low endotoxin albumin, Sigma-Aldrich, Zwijndrecht, The Nether-
lands), incubated for 30 minutes in the absence or in the presence of
various concentrations of anti-CCR antibodies (anti-CCR1: 1, 5 or
25 mg/ml; anti-CCR5: 1 or 5 mg/ml; anti-CCR2: 1, 5 or 25 mg/ml)
or respective isotype controls (5 or 25 mg/ml) or with the small
molecule CCR1 antagonist BX471 (1, 5 or 25 mg/ml). After
incubation, 1610
5 monocytes were transferred into the upper
chamber of 5 mM pore-size transwell plates (96 well ChemoTXH,
NeuroProbe, Gaithersburg, MA). Chemotaxis medium was added to
Table 1. Demographic and clinical data of patients
(chemotaxis).
Anti-CCR2 Anti-CCR5
CCR1
blockade
Sex, female/male (n) 8/0 (8) 7/1 (8) 5/8 (13)
Age in years, mean (range) 56.1 (44–72) 57.1 (41–78) 60.2 (40–81)
Disease duration, mean (range) 35.5 (2–108) 46 (4–120) 52.8 (1–232)
Rheumatoid factor positive, n (%) 4 (50%) 7 (87.5%) 10 (76.9%)
ACPA positive, n (%) 4 (50%) 6 (75%) 13 (90.9%)
SJC, mean (range) 6.7 (0–13) 1.6 (0–3) 5.0 (1–11)
TJC, mean (range) 8.5 (0–15) 5.8 (0–15) 7.6 (1–24)
ESR mm/h , mean (range) 21.6 (7–62) 32.7 (5–110) 18.4 (2–43)
CRP mg/liter, mean (range) 6.7 (1–21.7) 3.6 (2–4.8) 10 (0.6–34.4)
ACPA, anti-citrullinated protein/peptide antigens; SJC, swollen joint count; TJC,
tender joint count; ESR, erythrocyte sedimentation rate; CRP, C reactive protein.
doi:10.1371/journal.pone.0021772.t001
Table 2. Demographic and clinical data of patients (synovial
fluids).
Sex, female/male (n) 3/2 (5)
Age in years, mean (range) 52.8 (32–63)
Disease duration, mean (range) 217.8 (4–692)
Rheumatoid factor positive, n (%) 4 (80%)
ACPA positive, n (%) 3 (60%)
SJC, mean (range) 4 (1–9)
TJC, mean (range) 6 (1–15)
ESR mm/h , mean (range) 39.2 (16–58)
CRP mg/liter, mean (range) 26.2 (2.8–65.5)
ACPA, anti-citrullinated protein/peptide antigens; SJC, swollen joint count; TJC,
tender joint count; ESR, erythrocyte sedimentation rate; CRP, C reactive protein.
doi:10.1371/journal.pone.0021772.t002
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MCP-1 (100 ng/ml; R&D systems)or CCL5/RANTES(500 ng/ml;
Peprotech, Rocky Hill, NJ) or pooled RA SF (n=5 patients, 50%
diluted in chemotaxis medium). After 2 hours at 37uC, migration was
quantified by staining the cells that were attached to the membrane.
Briefly, after aspiration and removal of the cells from the top wellsthe
membrane was fixed in pre-chilled methanol (bottom side down)
followed by addition of DAPI solution to the membrane. After the
membrane was dried, it was mounted on an OptiPlate (bottom side
up) and the number of DAPI positive cells (cells that were trapped in
the membrane = migrated cells) was quantified using a multi-label
reader Victor3
TM (PerkinElmer, Inc., Waltham, MA). The DAPI
counts of empty wells (no addition of cells; background) were
subtracted from the wells containing cells. Data are expressed as
mean 6 SEM of migrated cells [counts (DAPI)].
Statistical analysis
Differences between groups were determined by unpaired t-test
using the program GraphPad Prism (version 4). P values ,0.05
were considered statistically significant.
Results
Chemokine levels in synovial fluid samples
The levels of CCR1, CCR2, and CCR5 ligands in the SFs were
[mean (range) ng/ml]: CCL2/MCP-1: 4.4 (1.0–9.0), CCL3/MIP-
1a: 5.6 (3.1–8.1), CCL4/MIP-1b: 9.4 (6.0–13) and CCL5/
RANTES: 2.8 (0.5–4.8).
Anti-CCR2 antibody treatment blocks
CCL2/MCP-1-induced but not SF-induced
HD and RA monocyte migration
As expected, CCL2/MCP-1 induced significant migration of
both HD (Fig 1A) and RA (Fig. 1B) monocytes pre-incubated with
medium (HD P=0.0358; RA P=0.0205) or isotype control (HD
P=0.0483; RA P=0.0005). Monocyte pre-incubation with anti-
CCR2 antibodies resulted in blockade of CCL2/MCP-1-induced
migration of cells derived from both HD (Fig. 1A; 5 or 25 mg/ml,
P=0.0147 and P=0.0035, respectively) and RA patients (Fig. 1B; 5
and 25 mg/ml, P=0.0226 and P=0.0009, respectively). There was
no effect of CCR2 blockade on spontaneous migration, except for
Figure 1. Anti-CCR2 blocks CCL2/MCP-1- but not SF-induced HD or RA monocyte migration. (A) HD monocyte migration induced by
CCL2/MCP-1. (B) HD monocyte migration induced by SF. (C) RA monocyte migration induced by CCL2/MCP-1. (D) RA monocyte migration induced by
SF. Data are expressed as mean 6 SEM (HD n=8; RA n=8).
doi:10.1371/journal.pone.0021772.g001
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P=0.0294).
Since in RA circulating monocytes are recruited to the synovial
compartment under the influence of chemotactic agents, we
mimicked this situation by using SF as chemoattractant in our in
vitro model. SF induced significant migration of both HD (Fig 1C)
and RA (Fig. 1D) monocytes pre-incubated with medium (HD
P=0.0153; RA P,0.0001 compared to migration in medium
control groups). Contrary to results for CCL2/MCP-1-induced
migration, SF-induced migration could not be blocked by anti-
CCR2 antibody treatment at any of the concentrations used.
The observation that monocytes from HD showed higher
chemotaxis compared to RA monocytes is not completely
understood, but might perhaps be explained by the fact that RA
monocytes exhibit lower expression levels for chemokine receptors
compared to HD, as previously shown [1].
Anti-CCR5 antibody treatment blocks CCL5/RANTES-induced
but not SF-induced RA monocyte migration
CCL5/RANTES induced significant migration of RA mono-
cytes (Fig. 2A) pre-incubated with medium (RA P=0.0199). Anti-
CCR5 antibody treatment also blocked CCL5/RANTES-induced
migration of RA monocytes (5 mg/ml, P=0.0198 compared to
isotype control).
While SF induced significant migration of RA monocytes
(Fig. 2B) pre-incubated with medium (RA P,0.0002), this
migration could not be blocked by anti-CCR5 antibody treatment.
Dual targeting of CCR2 and CCR5 does not significantly
block SF-induced RA monocyte migration
Having shown that blockade of either CCR2 or CCR5 could
not inibit SF-induced chemotaxis, we investigated whether
blockade of both chemokine receptors in combination would
result in effective inhibition of monocyte migration towards SF.
However, combined blockade of CCR2 and CCR5 did not
significantly inhibit SF-induced chemotaxis, even at the concen-
tration of 25 mg/ml (Figure 3).
CCR1 blockade inhibits both CCL5/RANTES- and
SF-induced RA monocyte migration
As receptors expressed by monocytes other than CCR2 and
CCR5 might also be involved in the recruitment of monocytes to
Figure 2. Anti-CCR5 blocks CCL5/RANTES- but not SF-induced RA monocyte migration. (A) RA monocyte migration induced by CCL5/
RANTES. (B) RA monocyte migration induced by SF. Data are expressed as mean 6 SEM (n=8).
doi:10.1371/journal.pone.0021772.g002
Figure 3. Dual targeting of CCR2 and CCR5 does not block SF-
induced RA monocyte migration. Data are expressed as mean 6
SEM (n=6).
doi:10.1371/journal.pone.0021772.g003
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blockade mightresult ininhibitionofCCL5/RANTES-and/orSF-
induced RA monocyte migration. Anti-CCR1 antibody treatment
blocked CCL5/RANTES-induced migration of RA monocytes
(1 mg/ml, P=0.0011; 5 mg/ml, P=0.0280 compared to isotype
control) (Fig. 4A). Similarly, the small molecule CCR1 antagonist
BX471 also blocked CCL5/RANTES-induced migration of RA
monocytes (1 mg/ml, P=0.0181; 5 mg/ml, P=0.0015; 25 mg/ml,
P=0.0118 compared to CCL5/RANTES) (Fig. 4C). In contrast to
CCR2 or CCR5 blockade, CCR1 blockade resulted in significant
reduction of monocyte migration towards SF (Fig. 4B and 4D) (for
anti-CCR1: 5 mg/ml, P=0.0441; 25 mg/ml, P=0.0197 compared
to isotype control; for small molecule CCR1 antagonist: 5 mg/ml,
P=0.0245; 25 mg/ml, P=0.0189 compared to CCL5/RANTES).
Discussion
In the present study we showed that specifically for CCR2 and
CCR5 blockade, ligand-induced RA peripheral blood monocyte
migration could be blocked by the respective receptor blocking
antibody (CCL2: anti-CCR2 or CCL5: anti-CCR5) but not when
RA SF was used as chemoattractant. Similarly, combined blockade
of CCR2 and CCR5 could not significantly inhibit migration of RA
peripheral blood monocytes towards SF in the in vitro chemotaxis
model.Incontrast,wewereabletoblockCCR1-mediatedmonocyte
migration induced by CCL5/RANTES or SF by using either a
CCR1 blocking antibody or a small molecule CCR1 antagonist.
We focused in this study on monocytes, as it has previously been
shown that numbers of monocytes/macrophages are related to
clinical signs and symptoms in RA [3]. Moreover, effective anti-
rheumatic treatments in RA induce a decrease in numbers of
synovial sublining macrophages, which correlate with clinical
improvement independently of the therapeutic strategy (reviewed
in [26]). If CCR2 or CCR5 blockade would work in RA, it should
be at least in part be via an effect on monocyte migration towards
the synovial compartment.
Chemokines and their receptors have been shown to participate
in a number of various biological processes and due to their
Figure 4. CCR1 blockade inhibits both CCL5/RANTES- and SF-induced RA monocyte migration (A) RA monocyte migration induced
by CCL5/RANTES and blocked by anti-CCR1 antibody. (B) RA monocyte migration induced by SF and blocked by anti-CCR1 antibody. (C) RA
monocyte migration induced by CCL5/RANTES and blocked by small molecule CCR1 antagonist (BX471). (D) RA monocyte migration induced by SF
and blocked by small molecule CCR1 antagonist (BX471). Data are expressed as mean 6 SEM (n=8).
doi:10.1371/journal.pone.0021772.g004
Chemokine Blockade in Rheumatoid Arthritis
PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e21772diverse role in autoimmune diseases have been considered good
therapeutic targets, in particular CCR2 and CCR5 for immune-
mediated inflammatory diseases of which RA is a prototype
disease [27–29]. In view of these observations, a number of
chemokine receptor antagonists (small molecule receptor antago-
nists and neutralizing antibodies to the receptor) have been
designed and tested in animal models and several clinical trials
[27,30]. While CCR2 and CCR5 receptor antagonists have shown
initial promise in pre-clinical studies [14,15,27], blockade of
CCR2 [16], its ligand CCL2 [31], and CCR5 [17,18] have failed
in clinical trials in RA patients [16–18]. The picture may be
different for CCR1 blockade. In a small, randomized clinical trial,
patients with active RA were treated for 2 weeks with the CCR1
antagonist CP-481,715 or placebo. In this proof-of-concept study,
treatment was administered with a dose of 300 mg given every
eight hours. Synovial tissue analysis revealed a marked decrease in
the total number of cells, especially in the number of macrophages
and CCR1
+ cells, after active treatment; only cells capable of
expressing CCR1 were affected [21]. The biological changes were
associated with a trend towards clinical improvement. A larger
phase II clinical trial used a reformulated version of CP-481,715
that was dosed twice a day. This study failed to demonstrate
clinical efficacy, which may be related to lower drug levels and
very high placebo responses in this study [23,32]. Another study
comparing the effects of another oral CCR1 antagonist, MLN3897,
at a dose of 10 mg once daily also failed to demonstrate clinical
efficacy compared to placebo at the levels of receptor occupancy
reached in that study [22].
There may be different explanations for the negative results in
the clinical trials. First, we cannot completely exclude the
possibility that the levels receptor occupancy needed to effectively
block the CCR2 or CCR5 were not achieved in the clinical trials.
However, the results presented here suggest that RA peripheral
blood monocyte migration towards RA SF cannot be effectively
blocked by targeting CCR2 or CCR5, as other chemokine
receptors may be more important. Second, CCR5 is expressed by
T regulatory cells in humans [33]. Therefore, the lack of efficacy of
treatment with a CCR5 antagonist could perhaps in part be
explained by inhibition of T regulatory cells. This may also be
relevant for the observation with the CCR2 antagonists, as CCR2
and CCR5 are very close in homology, and inhibitors often target
both [34].
Apart from these and other mechanisms, it has been suggested
that redundancy in the chemokine system may explain the failed
trials with CCR2and CCR5 antagonists. We found that SF-induced
monocyte chemotaxis was not affected when one chemokine
receptor was blocked, opposed to ligand (CCL2 or CCL5)-induced
monocyte chemotaxis. As in RA patients the synovial joint (tissue
and SF) contains several ligandsfor both CCR2and CCR5 [1,8–13]
that are responsible for monocyte recruitment to these compart-
ments (via many receptors such as CCR1 [21]), this redundancy
could have accounted for the observed chemokine receptor blockade
failure in both our in vitro model and in the clinical trials. However,
even whenCCR2and CCR5wereblockedsimultaneously(similarly
at high doses), we were not able to block SF-induced chemotaxis of
RA peripheral blood monocytes, suggesting that CCR2 and CCR5
may not be the crucial chemokine receptors promoting monocyte
migration towards the inflamed joint. We also might consider other
possible explanations for the lack of clinical improvement after
blockade of CCR2 or CCR5. In this respect we have showed by
monocyte scintigraphy that blocking only the influx of inflammatory
cells may be insufficient to induce clinical improvement [35], and it
may be important to target chemokine receptors that also interfere
with macrophage retention.
Our results suggest that, in contrast to blockade of CCR2 or
CCR5, blocking CCR1 may be sufficient to inhibit migration of
RA peripheral blood monocytes towards the inflamed synovial
compartment in RA. It is conceivable that high levels of CCR1
occupancy at all times are needed to induce clinical improvement
in RA, consistent with our original observations using 300 mg of
CP-481,715 every eight hours in RA patients [21].
In summary, CCR2 and CCR5 antagonism may have failed in
RA due to redundancy: other chemokine receptors may have
substituted for CCR2 and CCR5. In contrast, CCR1 blockade
may be sufficient to inhibit migration of RA peripheral blood
monocytes towards the synovial compartment in the continuous
presence of high levels of receptor occupancy. This notion is
supported by recent modeling studies [36].
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